Cargando…
Lonidamine potentiates the oncolytic efficiency of M1 virus independent of hexokinase 2 but via inhibition of antiviral immunity
BACKGROUND: Viruses are obligate parasites that depend on host cells to provide the energy and molecular precursors necessary for successful infection. The main component of virus-induced metabolic reprogramming is the activation of glycolysis, which provides biomolecular resources for viral replica...
Autores principales: | Cai, Jing, Zhu, Wenbo, Lin, Yuan, Hu, Jun, Liu, Xincheng, Xu, Wencang, Liu, Ying, Hu, Cheng, He, Songmin, Gong, Shoufang, Yan, Guangmei, Liang, Jiankai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607643/ https://www.ncbi.nlm.nih.gov/pubmed/33292203 http://dx.doi.org/10.1186/s12935-020-01598-w |
Ejemplares similares
-
Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1
por: Cai, Jing, et al.
Publicado: (2020) -
DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage
por: Xiao, Xiao, et al.
Publicado: (2018) -
Hexokinase inhibition using D-Mannoheptulose enhances oncolytic newcastle disease virus-mediated killing of breast cancer cells
por: Al-Ziaydi, Ahmed Ghdhban, et al.
Publicado: (2020) -
Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors
por: Song, Deli, et al.
Publicado: (2022) -
Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade
por: Liu, Yang, et al.
Publicado: (2020)